Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population
- PMID: 33590934
- DOI: 10.1111/liv.14828
Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population
Abstract
Data are limited on the epidemiological implications of the recent change in terminology from nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated fatty liver disease (MAFLD). We therefore performed a cross-sectional study of adults recruited in the 2017-2018 National Health and Nutrition Examination Survey, a representative sample of the general US population. The prevalence of NAFLD and MAFLD based on controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) obtained through vibration-controlled transient elastography (VCTE) were 37.1% (95% CI 34.0-40.4) and 39.1% (95% CI 36.3-42.1), respectively, with higher rates among Hispanic individuals. Agreement between the two definitions was high (Cohen's κ 0.92). Patients with NAFLD and MAFLD also showed similar risk of advanced liver fibrosis (7.5% and 7.4% respectively). Our results suggest that the recent change in diagnostic criteria did not affect the prevalence of the condition in the general United States population.
Keywords: Fibroscan; MAFLD; NAFLD; population; prevalence.
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
References
REFERENCES
-
- Eslam M, Newsome PN, Anstee QM, et al. A new definition for metabolic associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202-209.
-
- Lin S, Huang J, Wang M, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver International. 2020;40(9):2082-2089.
-
- Wong VW-S, Wong GL-H, Woo J, et al. Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease. Clin Gastroenterol Hepatol. 2020. https://doi.org/10.1016/j.cgh.2020.10.046
-
- Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(6):1717-1730.
-
- National Center for Health Statistics. National Health and Nutrition Examination Survey 2017-2018 Laboratory Data. Internet: https://wwwn.cdc.gov/nchs/nhanes/Search/DataPage.aspx?Component=Laborato... (accessed June 2020).
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
